6th Jun 2014 08:52
LONDON (Alliance News) - Scancell Holdings PLC said Friday its DNA Immunobody technology platform had been granted a patent by the US Patent and Trademark Office.
Scancell said the patent was key for the protection of its pipeline of vaccines utilising the technology. It has already been granted patents in Australia, China and Japan.
The company said it was continuing to develop the platform and advancing the trial of its SCIB1 ImmunoBody treatment for melanoma.
Shares in Scancell were trading up 2.0% at 32.88 pence Friday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Scancell Holdings